new launch recent acquisit contribut growth
maintain buy rate maintain
tp estim tp base
forward price-to-earnings multipl adjust ep
expect forward price/sal
provid upsid potenti
expect growth revenu
estim base follow factor strong
growth across segment acquisit made
year new product launch plan
sale increas due growth
across segment acquisit made year
total revenu estim
report ep adjust ep
estim
gener maximum revenu cardiovascular total
sale intervent cardiolog increas
sale peripher intervent increas
electrophysiolog busi revenu increas
neuromodul busi revenu
increas
mn except ep crispidea name corpor tickerbsxstock ratingbuyunchangedindustri viewoverweightpositivepric may week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth corporation| may
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
endoscopi deliv growth revenu
rich pipelin launch four new product
includ orca pod singl use valv oris gel endolumin
surgeri spyglass ds ii broader portfolio
solut pancreat biliari procedur
meaning innov focus execut help
deliv strong financi result bsx recent
acquisit ad variou product immens
potenti portfolio
part major develop close purchas
milliped enter agreement buy btg plc
complet btg buy-out expect gain
enhanc categori leadership posit intervent
oncolog arteri venou therapi
howev milliped like leverag posit
grow field mitral regurgit mr fall
receiv fda approv launch vercis
primari cell vercis gevia deep brain stimul db
system featur vercis cartesia direct lead
current price-to-earnings
due declin stock price price-to-earnings
volatil past due strong growth stock price
averag price-to-earnings expect
forward price-to-earnings
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend rate n/a forward annual dividend yield n/a trail annual dividend rate n/a trail annual dividend yield n/a year averag dividend yield n/a pay-out dividend date n/a ex-dividend date n/a last split factor new per last split date inform boston scientif corporation| may
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener restructur oper total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual quarterli actual annual corporation| may
 market account total prepaid current total current build machineri furnitur total fix non-curr total non-curr total equiti liabilitiesaccount accru total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item boston scientif corporation| may
provid oper activ decreas compar
decreas due payment ir tax settlement
use invest activ compar cash use
invest activ includ payment net cash acquir acquisit includ
augmenix nxthera cryterion medic inc claret nvision payment purchas
properti plant equip payment relat invest acquisit
certain technolog includ invest milliped inc
provid financ activ increas compar
defer incom oper increas decreas increas decreas current decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end corporation| may
report strong perform year due growth
across busi
report
basi
compar
total revenu increas report basi
compar total revenu increas
oper basi organ basi
total revenu increas compar
revenu emea europ middl east africa
increas compar
total revenu apac asia-pacif increas
compar total revenu latin america
canada increas compar
total revenu emerg market increas
compar
cog increas compar
gross profit increas compar
revenu emea
europ middl east
africa increas
compar
sg expens increas compar
 expens increas
compar royalti expens
amort expens compar
conting consider benefit compar
restructur charg compar
litigation-rel charg compar
oper incom flat
interest expens compar
incom compar expens
incom tax benefit compar incom tax expens
net incom compar
net loss adjust net incom
gaap ep increas compar
adjust ep compar
total revenu increas compar
increas includ oper growth posit impact
bp foreign currenc fluctuat
oper net sale includ due acquisit symeti
sa symeti nxthera inc nxthera claret medic inc
claret augmenix inc augmenix
total revenu increas compar
total revenu emea increas
compar
gaap ep increas
compar
compar
total revenu apac increas compar
total revenu latin america canada increas
compar
cog increas compar
gross profit increas compar
primari factor contribut increas gross profit margin
posit impact cost reduct result process improv
program restructur program favor period expens partial
off-set neg impact foreign currenc fluctuat
sg expens increas compar
sg expens net sale compar
decreas sg expens net sale due leverag
increas sale well benefit target initi focus
reduc sg expens end-to-end busi process streamlin
autom includ function expans global share servic robot
 expens increas compar
 expens net sale compar
 expens increas due invest across busi
order maintain pipelin new product
royalti expens increas compar
increas royalti expens relat increas sale partial off-set
expir royalti certain countri
amort expens increas compar
increas due amortiz intang asset acquir
part recent acquisit includ symeti nvision medic
corpor nvision nxthera augmenix
intang asset impair charg compar
conting consider benefit compar
restructur charg compar
litigation-rel charg compar
oper incom compar
interest expens compar
incom compar expens
incom tax benefit compar incom tax expens
net incom compar
adjust net incom ep
compar adjust ep compar
increas
due
gaap ep
compar
adjust
ep
compar
three report segment compris cardiovascular
rhythm manag medsurg repres aggreg
oper segment creat new segment rhythm neuro segment
includ cardiac rhythm manag electrophysiolog
neuromodul previous includ medsurg segment
total revenu cardiovascular segment increas
compar total revenu increas
compar
oper incom increas compar
oper margin compar
total revenu intervent cardiolog busi increas
compar total revenu increas
compar
compar
total revenu
increas
compar
total revenu increas
compar total intern revenu increas
compar
y/i increas relat structur heart therapi includ sale
watchman left atrial appendag closur laac devic acur
transcathet aortic valv replac tavr platform purchas part
part claret acquisit complex percutan coronari
total revenu peripher intervent increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
increas driven strong perform region particularli
asia pacif growth intervent oncolog product
eluvia drug elut vascular stent system core technolog treat
total revenu medsurg segment increas
compar total revenu increas
compar
total revenu
increas
compar
total revenu
medsurg increas
compar
oper incom increas compar
oper margin compar
urolog pelvic health
total revenu urolog pelvic health busi increas
compar total revenu
increas compar
total revenu increas
compar total intern revenu increas
compar
increas attribut growth sale stone franchis includ
lithovu digit flexibl ureteroscop men health product benign
prostat hyperplasia bph product famili includ rezum system
purchas part nxthera acquisit spaceoar hydrogel system
purchas part augmenix acquisit
total revenu endoscopi busi increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
increas driven growth hemostasi franchis featur
resolut clip biliari franchis spyglass ds direct
visual axio stent electrocauteri enhanc deliveri
infect prevent product patholog servic
total revenu
urolog pelvic health
busi increas
compar
total revenu
endoscopi increas
compar
rhythm neuro
total revenu rhythm neuro segment increas
compar total revenu increas
compar
oper incom increas compar
oper margin compar
total revenu electrophysiolog busi increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
increas driven global expans rhythmia map system
product capit equip offer expand portfolio navig
enabl open-irrig cathet includ blazer intellanav mifi open-
irrig cathet advanc diagnost cathet includ intellamap
total revenu neuromodul busi increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
total revenu
rhythm neuro
segment increas
compar
total revenu
busi increas
compar
rhythm neuro
increas driven success launch spectra wavewrit
spinal cord stimul system continu strong sale
growth vercis deep brain stimul db system
total revenu
compar
total revenu cardiac rhythm manag increas
compar total revenu flat
total revenu increas
compar total intern revenu decreas
compar
increas driven global strength implant cardiovert
defibril crt-d subcutan implant cardiac defibril s-
current gener crt-d product favor
impact magnet reson imag mri safe condit label
approv fda septemb launch
defibril growth also driven combin on-going global
commerci reson famili crt-d devic
includ heartlog heart failur hf diagnost increas market
penetr s-icd
reach agreement term recommend offer acquir btg
plc compani headquart unit kingdom develop
commerci product use minimally-invas procedur target
cancer vascular diseas well acut care pharmaceut
close acquisit milliped inc privately-held compani santa
rosa calif milliped iri transcathet annuloplasti ring system
develop treatment patient sever function mitral
regurgit fmr abl toler open-heart surgeri
studi assess safeti effect transcathet aortic valv
replac tavr lotu edg aortic valv system intermedi
surgic risk patient includ bicuspid valv
reach agreement corpor settl
outstand patent disput compani venu around
world term agreement edward made one-tim
payment boston scientif parti litig patent
disput relat current portfolio transcathet aortic valv tavr certain
mitral valv repair devic left atrial appendag closur laac devic
receiv food drug administr fda approv
mm diamet synergi everolimus-elut platinum chromium
coronari stent system first bioabsorb polym stent design earli
heal larg vessel
watchman left atrial appendag closur laac devic includ
updat american heart associ aha american colleg
cardiolog heart rhythm societi hr guidelin
manag patient atrial fibril af stroke risk reduct
option non-valvular af patient poor candid long-term oral
reach
agreement term
recommend offer
acquir btg plc
unit kingdom
develop
use minimally-
target cancer
vascular diseas well
acut care
receiv fda approv launch vercis primari cell
vercis gevia deep brain stimul db system featur vercis
cartesia direct lead new db system allow control rang
shape posit direct electr stimul tailor treatment
symptom patient suffer parkinson diseas
launch spyscop dsii access deliveri cathet upgrad
scope cholangiopancreatoscopi two new spyglass ds
accessori offer physician better visual pancreat bile
duct well addit tool manag difficult stone strictur
announc four-year result random clinic trial demonstr
rezm water vapor therapi minim invas treatment benign
prostat hyperplasia bph provid durabl result demonstr
surgic retreat rate preserv sexual function
launch advanc xp male sling system minim
invas solut treatment mild moder male stress urinari
incontin allow urologist treat men
appropri sling
launch
solut
treatment mild
allow
urologist treat
men
appropri sling
targetbusinessdescriptionclos datetarget commerciallaunchinvestmentmilliped structur hearttmvr full annuloplasti ring mitral ablat gi managementesophag temp pelvic healthminim invas therapi pelvic healthpotenti platform earlierdiagnosi ovarian managementsingl shot therapi -pulmonari vein structur heartembol protect tavr interventionsperipher venou pelvic healthorgan protect prostatecanc radiat boston scientif corporation| may
expect revenu growth rang report basi
organ basi oper basi
adjust ep expect rang
gaap ep expect rang
adjust gross margin expect rang
adjust oper margin expect rang
adjust tax rate expect
growth
rang
report basi
organ basi
oper basi
endoscopi
rich pipelin
oris gel endolumin
surgeri spyglass ds
ii broader
portfolio solut
boston scientif sale increas report basi
oper basi organ basi growth
due growth across busi segment recent acquisit made
ep adjust ep
gener maximum revenu cardiovascular total sale
intervent cardiolog increas sale peripher
intervent increas
endoscopi deliv growth revenu endoscopi rich
pipelin launch four new product includ orca pod singl use
valv oris gel endolumin surgeri spyglass ds ii broader
portfolio solut pancreat biliari procedur
global rhythm neuro oper organ sale grew
neuro modul oper organ revenu growth grew
year continu strength portfolio global commerci execut
reach agreement term recommend offer acquir btg
plc compani headquart unit kingdom develop
commerci product use minimally-invas procedur target cancer
vascular diseas well acut care pharmaceut
close acquisit milliped inc privately-held compani santa
rosa calif milliped iri transcathet annuloplasti ring system
develop treatment patient sever function mitral
regurgit fmr abl toler open-heart surgeri
receiv fda approv launch vercis primari cell vercis
gevia deep brain stimul db system featur vercis cartesia
meaning innov focus execut help deliv strong financi
result bsx recent acquisit ad variou product
immens potenti portfolio growth futur
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
revenu growth compar
gross margin compar
net margin increas compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corporation| may
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale boston scientif corporation| may
inv flow
mrqfinanci mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqreturn mrqreturn asset boston scientif corporation| may
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item boston scientif corporation| may
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc repurchas stock- net issuanc prefer stock- net issuanc dividends- net chang capit free boston scientif corporation| may
current price-to-earnings due declin stock price price-to-earnings
volatil past due strong growth stock price compar ep
averag price-to-earnings expect forward price-to-earnings
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluefmr vanguard group inc capit world wellington manag compani jp morgan primecap manag bollard group top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard specialized-health vanguard/primecap vanguard growth fund america new perspect fund fundament investor fidel contrafund fidel select portfolio medic technolog devic spdr etf corporation| may
develop receiv fda approv lotu edg aortic valv systemapril corpor announc receiv food drug administr fda approv lotu edg aortic valv system deliv via minimally-invas procedur transcathet aortic valv replac tavr technolog approv patient sever aortic stenosi consid high risk surgic valv replac via open heart surgeri receiv ce mark gener watchman flx left atrial appendag closur devicemarch corpor nyse announc receiv ce mark initi limit market releas next gener watchman flx left atrial appendag closur laac devic europ watchman left atrial appendag occlus devic intend reduc risk stroke peopl non-valvular af begun limit market releas watchman flx devic europ expect expand commerci addit site second half compani also plan begin enrol european patient post-approv registri come month launch vercis primari cell vercis gevia deep brain stimul system direct leadsjanuari corpor launch verciseprimari cell pc vercis gevia deep brain stimul db system featur vercis cartesia direct lead new system recent approv food drug administr fda featur technolog design allow physician control rang shape posit direct electr stimul treat symptom parkinson diseas pd highly-person therapi vercis cartesia direct lead first direct lead introduc global market launch ineuropein exercis option acquir milliped incdecemb corpor announc exercis option acquir remain share milliped inc privately-held compani insanta rosa calif upon recent success complet first-in-human clinic studi acquisit expand structur heart portfolio includ iri transcathet annuloplasti ring system develop treatment patient sever mitral regurgit mr abl toler open-heart surgeri corporation| may
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
higher
compar
roa roi roe
respect ttm basi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corporation| may
consensu view analyst trend stock
forecast lower
compar
 average
forward price-to-earnings
higher
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonbsxindustri avg avgprice/earn yield corporation| may
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim
averag revenu estim
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate corporation| may
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock volatil quarter dip march due fda uncertainti
led declin sector
stock declin past averag volum share trade past
stock price volatil past dip decemb
stock surg februari result
rang stock
stock price shown upward trend sinc past due growth busi
stock gave return past
deliv strong perform year due recent launch acquisit recommend
buy rate base perform year strong pipelin estim
tp base forward price-to-earnings multipl
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
